TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02260518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
Study: NCT03485209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg or 400mg given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg or 400mg given by IV
Study: NCT01738477

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Single dose intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: Single dose intramuscular administration.
Study: NCT03485209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg or 400mg given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100mg/m\^2 given by IV
Study: NCT00134628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: HBO at 2.0 ATA

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Normal air under pressure (1.1 ATA)
Study: NCT03341169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N(2)-L-Alanine L-Glutamine dipeptide
Description: :Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (0.9% NaCl (normal saline))
Description: Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Study: NCT01805947

Intervention type: BEHAVIORAL
Intervention: Lifestyle Modification
Description: Lifestyle Modification
Study: NCT00742469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02864472

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PDT
Description: PDT and ranibizumab

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Ranibizumab

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab PRN
Description: ranibizumab PRN

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab PRN
Description: ranibizumab PRN
Study: NCT01015833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT00578760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 325mg ASA OD for the duration of the cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: OD for course of cisplatin chemotherapy
Study: NCT02562235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
Study: NCT02759744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound image-guided ablation device
Description: ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
Study: NCT03658096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pressure monitor ultrasound system
Description: Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pressure monitor ultrasound system
Description: Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
Study: NCT01015833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT02622945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS plus Speech-Language Therapy
Description: Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
Study: NCT01015833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT00954109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: daily exercise: supervised treadmill walking or cycle ergometry use
Study: NCT01419431

Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: Inflammatory response in laparoscopic surgery
Study: NCT03663088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPR-A
Description: Standard Global postural re-education physiotherapy scoliosis specific exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPR-B
Description: Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
Study: NCT02622945

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham plus Speech-Language Therapy
Description: Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
Study: NCT00486837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-Proteinase Inhibitor (Human)
Description: 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-Proteinase Inhibitor (Human)
Description: 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
Study: NCT03104101

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TPTNS+Drug
Description: one tablet Trospium Chloride 20 mg once daily Plus TPTNS
Study: NCT04360382

Intervention type: OTHER
Intervention: ERACS
Description: Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.

Intervention type: OTHER
Intervention: ERACS
Description: Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.

Intervention type: OTHER
Intervention: Regular care
Description: Usual care for all cases subjected to cesarean section at our hospital.

Intervention type: OTHER
Intervention: Regular care
Description: Usual care for all cases subjected to cesarean section at our hospital.
Study: NCT04610528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3 1402
Description: 6.4 mg/kg dose
Study: NCT02365480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Chloride
Description: Given PO
Study: NCT03104101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TPTNS
Description: Surface adhesive electrodes placed on the skin above medial malleolus
Study: NCT04610528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3 1402
Description: 5.6 mg/kg dose
Study: NCT02365480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT03238014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
Study: NCT02055638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00815555

Intervention type: OTHER
Intervention: There is no intervention - this is an observational study
Study: NCT03817086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand coordination and mental practice
Description: 20 chronic (\>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand coordination and action observation
Description: In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
Study: NCT03692819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 Mg
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
Study: NCT01988090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 IU Vitamin D Supplement
Description: Standard Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50,000 IU Vitamin D supplement
Description: High Dose
Study: NCT04659421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined therapy with rh-ES and CV
Description: All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Study: NCT01206153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study: NCT02102425

Intervention type: PROCEDURE
Intervention: Patients with or without bandage over exit site
Study: NCT00017953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
Study: NCT00936871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 2400 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine (if necessary)
Description: Lersivirine 2100 mg single dose (if necessary)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg single dose
Study: NCT02770963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3\*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3\*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Specially designed sham needles (0.3\*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients.
Study: NCT02545153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tisseel, Baxter (Aprotinin and Fibrinogen)
Description: After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No fibrin sealant applied
Study: NCT02589964

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Florajen-3
Description: The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
Study: NCT01914497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acutus Medical System Mapping
Study: NCT03512366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Desarda's technique
Description: It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein's technique
Description: A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
Study: NCT04624412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Moderate Intensity Exercise
Description: Continuous Aerobic Moderate Intensity Exercise~* 5-10 min warm up~* 30 min moderate aerobic exercise (Treadmill walking exercise)~* Constant intensity at 50% - 70% of max HR (3-6 METS)~* 5-10 min cool down
Study: NCT01734317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Description: A soft silicone wound contact layer.
Study: NCT01658657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Study: NCT04624412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic (Mild intensity Exercise)
Description: Continuous Aerobic (Mild intensity Exercise)~* 5-10 min warm up~* 30 min mild aerobic exercise (Treadmill walking exercise)~* Constant intensity at 30-50 % of max HR (1-3 METS)~* 5-10 min cool down
Study: NCT04559347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine (EXPAREL®)/Bupivacaine
Description: Single shot for erector spinae block
Study: NCT01658657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril/hydrochlorothiazide
Description: This is a combination pill